Should I Buy RAPP? RAPP 2026 Analysis

Should You Buy Rapport Therapeutics Inc (RAPP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

26.750

1 Day change

1.17%

52 Week Range

42.270

Analysis Updated At

2026/01/26

Rapport Therapeutics (RAPP) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 investment capital. The stock has strong positive catalysts, including bullish analyst ratings with high price targets, a promising drug pipeline, and improving financial metrics. While technical indicators are neutral and there are no immediate trading signals, the long-term growth potential outweighs short-term uncertainties.

Technical Analysis

The MACD histogram is negative (-0.18) but contracting, suggesting potential stabilization. RSI is neutral at 44.883, and moving averages are converging, indicating no strong trend. Key support and resistance levels are S1: 25.945, Pivot: 27.576, and R1: 29.207. The stock is trading near support levels, which could present a good entry point.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analysts are highly bullish, with price targets of $47 and $80, citing confidence in RAP-219's Phase 3 trials and potential approval.
Financial performance shows significant improvement in net income (+53.53% YoY) and EPS (+42.00% YoY).
Stock trend analysis indicates a 7.68% potential upside in the next month.

Neutral/Negative Catalysts

Lack of recent news or event-driven catalysts.
Neutral sentiment from hedge funds and insiders.
Technical indicators are not strongly bullish, and the stock is trading in a neutral zone.

Financial Performance

In Q3 2025, the company reported no revenue growth but showed significant improvement in net income (-$26.93M, up 53.53% YoY) and EPS (-0.71, up 42.00% YoY). These metrics indicate better cost management and operational efficiency.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish on RAPP, with BTIG initiating coverage with a Buy rating and a $47 price target, and Citizens JMP raising the price target to $80. Both firms express high confidence in the success of RAP-219's trials and its market potential.

7 Analyst Rating

Wall Street analysts forecast RAPP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPP is 54.6 USD with a low forecast of 40 USD and a high forecast of 80 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 26.440

Low

Averages

54.6

High

Current: 26.440

Low

Averages

54.6

High

BTIG

NULL -> Buy

initiated

$47

AI Analysis

2025-11-18

Reason

BTIG

Price Target

$47

AI Analysis

2025-11-18

initiated

NULL -> Buy

Reason

BTIG initiated coverage of Rapport Therapeutics with a Buy rating and $47 price target. Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule medications for neurological and psychiatric conditions, the analyst tells investors in a research note. BTIG has a high degree of confidence that the Phase 3 registrational focal epilepsy trials for RAP-219 will be successful and that the drug will receive approval.

Citizens JMP

Outperform

maintain

$77 -> $80

2025-11-07

Reason

Citizens JMP

Price Target

$77 -> $80

2025-11-07

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Rapport Therapeutics to $80 from $77 and keeps an Outperform rating on the shares. Rapport reported Q3 results and said it continues to advance RAP-219 development, the analyst tells investors in a research note. The firm continues to believe that the results from the Phase 2a proof-of-concept study evaluating RAP-219 in focal epilepsy can be rapidly and broadly adopted in clinical practice.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RAPP

Unlock Now

RAPP Should I Buy

RAPP Should I Buy

Should You Buy Rapport Therapeutics Inc (RAPP) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch